Anlotinib Dihydrochloride

盐酸安罗替尼

Report date: 2026/04/17 20:02:02
NME

Base Information

Drug NameAnlotinib Dihydrochloride
Drug Alias NameAnlotinib hydrochlorideCatequentinibAndrotinib福可维AL-3818
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptor 3 antagonistsVascular endothelial growth factor receptor 3 antagonistsFibroblast growth factor receptor 1 antagonists +[8] 
TargetsVascular endothelial growth factor receptor 1Stem cell growth factor receptorVascular endothelial growth factor receptor 3 +[8] 
Therapy Area/IndicationsMedullary thyroid cancer (MTC)Liver DysfunctionGastroesophageal Junction Neoplasms +[43] 
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryMainland China
Original Approved Date2018/05/08
Country/TerritoryUnited StatesItalyUnited Kingdom +[6] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAdvenchen Laboratories LlcJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesAdvenchen Laboratories LlcThe First Affiliated Hospital With Nanjing Medical UniversityNanfang Hospital Of Southern Medical University +[8] 
Inactive CompaniesCttqNational Cancer Center ChinaFudan University +[6] 
Active IndicationsMedullary thyroid cancer (MTC)Liver DysfunctionLung Diseases, Interstitial +[28] 
Inactive IndicationsGastroesophageal Junction NeoplasmsGastroenteropancreatic neuroendocrine tumorSolid tumours +[15] 

Other Information

ATC CodeL01XE
Related LinksN/A